We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Vernalis | LSE:VER | London | Ordinary Share | GB00B3Y5L754 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 6.17 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
25/8/2009 11:44 | Lets hope it gets noticed by other investors! | fhmktg | |
25/8/2009 11:16 | very nice write up by GCI, thanks for that investinggarden | shaid1 | |
25/8/2009 11:09 | Buy recommendation from Growth Company Investor | investinggarden | |
25/8/2009 09:56 | cest well said, denarii has come on this thread to disrupt it. he does the same on other threads. | shaid1 | |
25/8/2009 09:31 | Don't remember Glaxo investing in either of those. DYOR and maybe you will find out. | cestnous | |
24/8/2009 16:53 | Shaid. See below but they are not necessarily recommendations!!! RHEP VRP CZA VLK EGX APF PRL ANR VIY EROS Losing bigtime in MTA and TMAN from last year. But the former is coming back and if the latter re-lists it could yet come good. And about a dozen starter posns. in others. | cestnous | |
24/8/2009 16:38 | cest good lad. what else u into? | shaid1 | |
24/8/2009 16:31 | In case anyone is wondering, this slight drop is not due to the Insti selling; The movement is due to the | | | increase in the issued share | | | capital as a result of the shares | | | issued to GSK, announced on 20 | | | August 2009. | cestnous | |
19/8/2009 12:06 | nous agreed, i think this and eros will be huge inside 12 months. Im also in UNIQ and think that will do very very well. Rainmaker and 2baffled on there are very very good posters. | shaid1 | |
19/8/2009 12:03 | Looks like its just me and you Shaid. Well why share the profits ? See you'r into EROS. That's my biggest holding at the moment. I think we are both going to be rich. | cestnous | |
18/8/2009 20:53 | hopefully we'll be in before the herd arrives. i hope they arrive at 300p plus. lol | shaid1 | |
18/8/2009 20:53 | Nous, i read it too and agree it was hugely bullish, if these can get to around 500p within 12 months we'll both be quids in imho. GSK taking shares at 87p is a massive bonus imho. | shaid1 | |
18/8/2009 16:32 | Yes I have Shaid1. It was indeed bullish, but I am afraid that I do not go a lot on charts analysis. The author however seems to have been taking the other good things in to account and after watching for a long time, this just smells to me like it is developing momentum, especially at a time of uncertainty, when many authorities seem to see the pharma sector as 'defensive'. Best of luck Nous | cestnous | |
18/8/2009 16:26 | cestnous have you read the shares article from last week...it was hugely bullish. | shaid1 | |
18/8/2009 16:20 | Well that's me in; watched for a while and hopefully now its going somewhere! | cestnous | |
17/8/2009 12:49 | virtually all buys today spread is very very tight now. Shares article was very positive last thursday. | shaid1 | |
17/8/2009 08:20 | free stock charts from www.advfn.com TIPPED IN SHARES MAGAZINE ON 13 AUGUST TO REACH 218p THEN MOVE ONTO 498p 6th august 09 - Under the terms of the deal Vernalis will receive $6 million upon signing (including a $3 million equity subscription by GSK for 2,040,542 new ordinary shares in Vernalis at a subscription price of 87 pence per share) and is eligible to earn up-front and potential milestone payments in excess of $200 million and up to double digit royalties based on worldwide sales of an oncology product. Further milestones and royalties could be earned should products against the target be developed for indications outside of oncology. | shaid1 | |
06/8/2009 17:23 | news seems to be out in many different forms today.. Drug developer Vernalis has signed an exclusive collaboration, option and license agreement with GlaxoSmithKline relating to a Vernalis research programme against an undisclosed oncology target. Under the terms of the deal, Vernalis will receive $6m upon signing (including a $3m equity subscription by GSK for 2.04m shares at 87p per share) and is eligible to earn up-front and potential milestone payments in excess of $200m. | 4screws | |
06/8/2009 16:01 | some interesting trades shwon as sells, probably buys 2173x92 at a time ...resulting in over £30k trades.... now reduced my loss to 46% of investment, pyschologivcally under that 50%, so will hold and hold and hold...how long too break even...welll have beeen here through thick and thin for years and in 6 months the new team seem to be performing very well. I hold. | 4screws | |
06/8/2009 08:20 | Rock solid results and a decent collaboration. Hopefully the tie up with give VER more inches in the press when trial results are announced. Nothing extrordinary, but have come to expect that from this stock. | vow | |
06/8/2009 08:20 | I would not like to suggest to anyone whether to buy into any share and everyone should DYOR.....but the news this morning is good....... ....and with a name like yours....being lucky..... | jwoolley | |
06/8/2009 08:17 | Yes, I am here, but I am new to this thread so probably not much use to you. Was just trying to decide wether to buy in. | lucky_lady |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions